The medicine remdesivir, from Gilead Sciences, had little or almost no effect on hospitalization times or chances of survival for patients in the covid-19, concluded a study by the World Health Organization (WHO).
Antiviral medication, one of the first to be used as a treatment for covid-19, was one of the drugs used to treat US President Donald Trump after his coronavirus infection.
The results are from the WHO “Solidarity” study, which evaluated the effects of four treatments with medications that included remdesivir, hydroxychloroquine, and the combination of lopinavir / ritonavir and interferon (used to treat HIV) in 11,266 patients adults in more than 30 countries.
The study concluded that the protocols appeared to have little or no effect on reducing mortality over 28 days or on the duration of hospital treatment among inpatients with Covid-19, the WHO said on Thursday.
The research results will still be reviewed and were published on the MedRxiv server before being published in a scientific journal.
Earlier this month, data from a North American study with remdesivir by Gilead showed that the treatment cut Covid-19’s recovery time by five days when compared to patients who received the placebo in a test involving 1,062 patients.